Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...